Augmedix, Inc. revised revenue guidance for the fourth quarter and full year ended December 31, 2023. Revenue in the fourth quarter of 2023 is expected to be approximately $12.5 million, exceeding guidance of $12.3 million, and resulting in full-year 2023 revenue of approximately $44.7 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.21 USD | -1.63% | -45.62% | -79.32% |
14/05 | Maxim Downgrades Augmedix to Hold From Buy | MT |
14/05 | B. Riley Adjusts Price Target on Augmedix to $3 From $5.50, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-79.32% | 58.98M | |
+14.85% | 70.23B | |
+5.12% | 17.08B | |
+12.12% | 13.77B | |
+20.33% | 13.57B | |
+16.67% | 10.15B | |
-19.27% | 7.04B | |
-1.15% | 6.18B | |
+3.30% | 5.27B | |
+1.07% | 5.06B |
- Stock Market
- Equities
- AUGX Stock
- News Augmedix, Inc.
- Augmedix, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023